ADAG Adagene Inc.

FDA Catalyst Company
2.98
-0.14  -5%
Previous Close 3.12
Open 3.07
52 Week Low 2.89
52 Week High 20.9799
Market Cap $130,287,382
Shares 43,794,078
Float 43,794,078
Enterprise Value $-27,198,759
Volume 19,952
Av. Daily Volume 37,598
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/01/2022
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/06/2022
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/16/2021
China Renaissance Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 06/25/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/08/2021
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/08/2021

Latest News

  1. SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company's management will participate in the following upcoming investor conferences:

    In-Person Conferences

    • Jefferies Global Healthcare Conference: Adagene will make a live Fireside Chat presentation on Wednesday, June 8 at 4:30 p.m. Eastern Time (US). The presentation will be webcast and a replay available in the Investors section of the company's website for at least 30 days. Management will also participate in one-on-one investor meetings at the conference to be held in New York, the United States.        

    • Goldman
    View Full Article
  2. - Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities –

    - IND or equivalent filings planned for two new product candidates in 2022, including masked anti-CD137 antibody with Fc engineering and masked anti-CD47 antibody, designed to enhance both safety and efficacy -

    SAN DIEGO and SUZHOU, China, April 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates. Data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, taking…

    View Full Article
  3. - 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater efficacy through higher and more frequent dosing -

    - Advanced three wholly-owned clinical programs both in single agent and combination trials -

    - Advanced five IND-enabling programs, including two on track for IND or equivalent filing in 2022 -

    - Established Sanofi technology licensing collaboration with potential value over US$2.5 billion, endorsing both SAFEbody® platform and pipeline, while advancing collaboration with Exelixis -

    - Strong cash position and efficient operations support expected milestones -

    SAN DIEGO and SUZHOU, China, March…

    View Full Article
  4. – ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific –

    – First SAFEbody candidate to advance into combination clinical trial, building on strong single-agent clinical profile –

    SAN DIEGO and SUZHOU, China, March 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab. The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumors at multiple sites in the U.S. and Asia Pacific…

    View Full Article
  5. - New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company's AI-powered platform -

    - SAFEbody® precision masking technology integrated across antibody-based modalities in POWERbody® candidates, designed to further enhance efficacy with secured safety -

    - Data show safe, powerful and durable immunotherapy for solid tumors can be achieved through combination of the fundamental mechanisms and pathways across the cancer immunity cycle -

    SAN DIEGO and SUZHOU, China, March 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced publication…

    View Full Article
View All Adagene Inc. News